The ‘617 project represents a breakthrough in cancer treatment with its dual-action CDK7 inhibitor designed for enhanced safety and efficacy. Positioned to potentially improve outcomes for patients with solid tumours, the project has moved into Phase 1/2 clinical trials, testing its hypothesis in real-world settings.

Basic information

Country

UK

Group Name

Exscientia

Source

Source